{"paperId": "60810f2441ea2306cd2a687de5bc27902e1ada6a", "publicationVenue": {"id": "b584320a-9e3c-4c68-a677-a15f68472cb6", "name": "Alimentary Pharmacology and Therapeutics", "type": "journal", "alternate_names": ["Aliment Pharmacol Ther", "Aliment Pharmacol  Ther", "Alimentary Pharmacology & Therapeutics"], "issn": "0269-2813", "url": "http://www3.interscience.wiley.com/journal/117987555/home", "alternate_urls": ["https://onlinelibrary.wiley.com/journal/13652036"]}, "title": "Review article: Externally derived control arms\u2014An opportunity for clinical trials in inflammatory bowel disease?", "abstract": "One of the greatest challenges in the current IBD clinical trial landscape is, perhaps, the recruitment and retention of eligible participants. Seamless testing of promising investigational compounds is paramount to address unmet needs, but this is hindered by a number of barriers, particularly patient concerns of placebo assignment.", "venue": "Alimentary Pharmacology and Therapeutics", "year": 2023, "fieldsOfStudy": ["Medicine"], "publicationTypes": ["Review", "JournalArticle"], "publicationDate": "2023-08-21", "journal": {"name": "Alimentary Pharmacology & Therapeutics", "pages": "659 - 667", "volume": "58"}, "authors": [{"authorId": "90574466", "name": "S. Honap"}, {"authorId": "1387474555", "name": "L. Peyrin-Biroulet"}], "citations": []}
